Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics:
- Introduction (00:00)
- Overview of Ovarian Cancer (OC) (2:12)
- Role of PARP Inhibitors in Advanced OC (4:56)
- Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)
- Role of Relacorilant in Advanced OC (57:08)
- Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)
NCPD information and select publications
